Login to Your Account



Affitech's AT001 Enters Clinic, as Delisting Looms

By Cormac Sheridan
Staff Writer

Monday, August 20, 2012

Clinical testing of Affitech A/S' lead antibody, AT001/r84, began this week, just as the company enters its final weeks as a publicly quoted entity and prepares to become a private entity, wholly owned by Russian investors.

Next week, the antibody developer will learn the outcome of a tender process for the remaining 15 percent of its stock that is not already owned by its majority shareholder, Trans Nova Investments Ltd., or an allied entity, Krosalter Enterprises Ltd.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription